INSIDER
01Overview02Follow the Money03Daily Brief04Live05Congress06Corporate Insiders07Government Money08Political Influence09Institutions10Washington Network11Follow the Power12Disclosure Clock13AI Investigator14Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
Data sources

Public disclosures only. Scores flag unusual patterns and are not evidence of wrongdoing. Not investment advice.

RH CHAIN…
OverviewFollow the MoneyDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
01Overview02Follow the Money03Daily Brief04Live05Congress06Corporate Insiders07Government Money08Political Influence09Institutions10Washington Network11Follow the Power12Disclosure Clock13AI Investigator14Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
OverviewFollow the MoneyDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
Data sources
SEC FORM 44h ago
HOUSE PTR4h ago
SEC 13F4h ago
ROBINHOOD CHAIN4h ago
SEC FORM 4/Option exerciseVerified data

Chakma Justin reported SPRY

Chief Business Officer · ARS Pharmaceuticals, Inc. · ARS Pharmaceuticals, Inc. — Stock Option (Right to Buy)

Side
M
Value
—
Shares
30.0K
Price
—
Executed
Nov 12, 2025
Disclosed
Nov 14, 2025
Disclosure timeline2 days from execution to publication · legal deadline 2 business days
Nov 12 executedNov 14, 2025 disclosed

SPRY · daily

Yahoo Finance chart API
▲Execution▼Disclosure●Material company filing●Other disclosed buy●Other disclosed sellUnofficial public endpoint; daily OHLCV, split-adjusted. Replace with a licensed feed for production.

Insider Score

Experimental signal
21/ 100 · ROUTINE
Methodology →
  • Transaction type0 / 20

    Option exercise — administrative, little informational value

  • Relative size+13 / 25

No reported dollar value · 50.8% of prior position

  • Filing timing0 / 15

    Disclosed 2 business days after execution (deadline: 2)

  • Historical behavior+8 / 15

    First recorded trade by this actor in this security

  • Frequency & clustering0 / 15

    No clustered activity in the dataset

  • Market events0 / 10

    No material company filing within 60 days after the trade

    • The Insider Score measures how far a disclosure deviates from normal filing patterns. A high score is a prompt for research, not evidence of illegal insider trading.

    Other disclosed activity · SPRY

    ScoreActorSecuritySideValueExecutedDisclosedLagSourceEvidence
    9
    SL
    Slebir John LChief Legal Officer
    SPRYARS Pharmaceuticals, Inc.
    Grant or award
    		A—
    1.20M sh
    		Nov 2, 2026Nov 4, 2026
    traded Nov 2, 2026
    		+2dSEC FORM 4

    Evidence

    9
    CD
    Casale DonnDirector, President and CEO
    SPRYARS Pharmaceuticals, Inc.
    Grant or award
    		A—
    1.04M sh
    		Oct 1, 2026Oct 5, 2026
    traded Oct 1, 2026
    		+4dSEC FORM 4

    Evidence

    9
    SE
    Smith Margaret EkinsChief Commercial Officer
    SPRYARS Pharmaceuticals, Inc.
    Grant or award
    		A—
    1.00M sh
    		Sep 1, 2026Sep 2, 2026
    traded Sep 1, 2026
    		+1dSEC FORM 4

    Evidence

    9
    CD
    Casale DonnPresident
    SPRYARS Pharmaceuticals, Inc.
    Grant or award
    		A—
    898.5K sh
    		Jul 1, 2026Jul 2, 2026
    traded Jul 1, 2026
    		+1dSEC FORM 4

    Evidence

    9
    KM
    Kelly MichaelDirector
    SPRYARS Pharmaceuticals, Inc.
    Grant or award
    		A—
    30.0K sh
    		Jun 24, 2026Jun 26, 2026
    traded Jun 24, 2026
    		+2dSEC FORM 4

    Evidence

    23
    KE
    Karas EricChief Commercial Officer
    SPRYARS Pharmaceuticals, Inc.
    Open-market sale · 10b5-1 plan
    		SELL$250K
    25.0K sh
    		Jun 12, 2026Jun 12, 2026
    traded Jun 12, 2026
    		+0dSEC FORM 4

    Evidence

    11
    KE
    Karas EricChief Commercial Officer
    SPRYARS Pharmaceuticals, Inc.
    Option exercise · 10b5-1 plan
    		M$38K
    25.0K sh
    		Jun 12, 2026Jun 12, 2026
    traded Jun 12, 2026
    		+0dSEC FORM 4

    Evidence

    3
    KE
    Karas EricChief Commercial Officer
    SPRYARS Pharmaceuticals, Inc.
    Option exercise · 10b5-1 plan
    		M—
    25.0K sh
    		Jun 12, 2026Jun 12, 2026
    traded Jun 12, 2026
    		+0dSEC FORM 4

    Evidence

    42
    CJ
    Chakma JustinChief Business Officer
    SPRYARS Pharmaceuticals, Inc.
    Open-market sale
    		SELL$1.21M
    136.4K sh
    		Nov 12, 2025Nov 14, 2025
    traded Nov 12, 2025
    		+2dSEC FORM 4

    Evidence

    31
    CJ
    Chakma JustinChief Business Officer
    SPRYARS Pharmaceuticals, Inc.
    Open-market sale
    		SELL$267K
    30.0K sh
    		Nov 12, 2025Nov 14, 2025
    traded Nov 12, 2025
    		+2dSEC FORM 4

    Evidence

    17
    CJ
    Chakma JustinChief Business Officer
    SPRYARS Pharmaceuticals, Inc.
    Option exercise
    		M$25K
    30.0K sh
    		Nov 12, 2025Nov 14, 2025
    traded Nov 12, 2025
    		+2dSEC FORM 4

    Evidence

    Evidence

    Verified data

    Read directly from the primary public document; every field below is as reported by the filer.

    Source

    Document
    SEC Form 4
    Publisher
    U.S. Securities and Exchange Commission (EDGAR)
    Document ID
    0001951238-25-000005
    Machine-readable
    Structured copy

    Timestamps

    Event (reported)
    Nov 12, 2025
    Published
    Nov 14, 2025
    Ingested by INSIDER
    Nov 5, 04:33 UTC
    Last re-read
    Nov 5, 04:33 UTC

    Extracted facts

    Filer
    Chakma Justin
    Role
    Chief Business Officer
    Transaction
    Option exerciseAs filed: “M”
    Asset
    ARS Pharmaceuticals, Inc. — Stock Option (Right to Buy)
    Ticker
    SPRY
    Shares
    30.0K
    Price per share
    $0
    Execution date (reported)
    Nov 12, 2025
    Owned after transaction
    89.0K shares
    Days from execution to publication
    2

    What this establishes

    Chakma Justin filed this Form 4 reporting a option exercise of SPRY on Nov 12, 2025. It became public on Nov 14, 2025. The filing establishes the reported transaction and the filer's stated role. It does not establish why the trade was made or what the filer knew.

    Extraction

    Method
    Form 4 XML
    Confidence
    1.00
    Chief Business Officer
    Chakma Justincik:0001951238
    Issuer
    ARS Pharmaceuticals, Inc.cik:0001671858

    Revision history · 0

    No field has changed since this record was first ingested.

    Company events

    No records

    No material filings recorded for this issuer.